MSF welcomes Indian Patent Office’s rejection of J&J’s application for paediatric formulation of lifesaving TB drug
July 17, 2024Mumbai, 17 July 2024 – On Friday 5 July 2024, the “pre-grant opposition” filed in December 2020 by The Delhi Network of Positive People (DNP+) and a Mumbai-based tuberculosis (TB) survivor Ganesh Acharya, and supported by Médecins Sans Frontières/Doctors Without...
Read more
MSF and Health Justice Initiative welcome J&J’s withdrawal of patents on lifesaving TB drug in South Africa
July 8, 2024The patent withdrawal is a result of an unprecedented investigation by South Africa’s Competition Commission into J&J We welcome today’s news that following the Competition Commission’s investigation initiation into anti-competitive practice, J&J has officially withdrawn its secondary patents in South...
Read more
Secrets Cost Lives: Transparency and access to medical products
July 5, 2024As an international medical humanitarian organisation, Médecins Sans Frontières/Doctors Without Borders (MSF) has repeatedly witnessed how the world’s most vulnerable people are left without access to the lifesaving medicines, diagnostics tests and vaccines they need. Ensuring access to these medical...
Read more
Danaher continues to charge exorbitant prices for lifesaving medical tests despite urgent demands for price reductions by several Ministries of Health
June 18, 2024Geneva, 17 June 2024 - In September 2023, the US corporation Danaher, which owns diagnostics maker Cepheid, announced a price reduction of the primary GeneXpert test used to diagnose tuberculosis (TB), from US$9.98 to $7.97, amid pressure from TB activists....
Read more
Urgent call for Europe to improve treatment access for tuberculosis: Many TB medicines and formulations accessible in lower- and middle-income countries remain unaffordable or unavailable in Europe
June 7, 2024Berlin, 6 June 2024: As the World Health Organization (WHO) concluded a meeting with European health officials and civil society to improve access to tuberculosis (TB) medicines in the European Union (EU)/European Economic Area (EEA), Médecins Sans Frontières/Doctors Without Borders...
Read more
Gavi’s next strategy must make sure to reach the 10 million children in fragile and humanitarian settings who are missing vaccines
June 4, 2024Where are we now? This week, on 6-7 June 2024, the Board of Gavi, the Vaccine Alliance, is meeting in Geneva to approve and endorse the one-page framework for Gavi 6.0, which outlines its strategy for the five-year period from...
Read more
As Gavi plans next five-year strategy, it must do more to get vaccines to people excluded from vaccination
April 16, 2024With routine vaccination efforts failing to reach people in fragile and emergency settings, MSF is seeing low vaccination coverage and more outbreaks of vaccine-preventable diseases, like diphtheria and measles Geneva, 15 April 2024 – Ahead of Gavi, the Vaccine Alliance’s Board...
Read more
Time for $5: MSF demands Cepheid and Danaher lower the price of medical tests
March 22, 2024Help us stop the profiteering on medical tests Sign the petition to demand drug manufacturers Cepheid and Danaher drop the price of GeneXpert tests for low- and middle-income countries. MSF and partners protest outside Danaher in Washington, DC, demanding price...
Read more
MSF response to signing of EFTA-India trade agreement
March 12, 2024Geneva/Delhi, 12 March 2024: On 10 March 2024, it was announced that India and the European Free Trade Association (EFTA) signed a free trade agreement (FTA) they have been negotiating since 2006. Full text of agreement along with Annex and the Record...
Read more
MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease
November 7, 2023The World Health Organization’s (WHO) 2023 Global Tuberculosis (TB) Report released today shows that the estimated global incidence of TB in 2022 remains unacceptably high, including for the more difficult to treat form of this disease, drug-resistant TB (DR-TB). With...
Read more
MSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction
September 19, 2023Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test. This reduction is a significant step, considering the...
Read more
Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need
September 12, 2023TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...
Read more
